[Objectives]To prepare 20(S)-protopanaxadiol PLGA nanoparticles(20(S)-PPD-PLGA-NPs).[Methods]20(S)-PPD-PLGA-NPs were prepared by emulsion solvent evaporation method,and the optimal formulation was screened by Box-Behn...[Objectives]To prepare 20(S)-protopanaxadiol PLGA nanoparticles(20(S)-PPD-PLGA-NPs).[Methods]20(S)-PPD-PLGA-NPs were prepared by emulsion solvent evaporation method,and the optimal formulation was screened by Box-Behnken experiment with particle size and drug loading as the indicators through single factor experiment,and the drug release in vitro was carried out.[Results]The average diameter of the nanoparticles was(119.60±2.29)nm and the polydispersity index was(0.12±0.02),the size was uniform.The encapsulation efficiency and drug loading of protopanaxadiol were(87.99±1.29)%and(14.86±0.25)%,respectively.[Conclusions]The 20(S)-PPD-PLGA-NPs were successfully prepared by emulsion solvent evaporation method,and the 20(S)-PPD-PLGA-NPs had good stability,to lay a foundation for the study of 20(S)-PPD-PLGA-NPs in vitro and in vivo.展开更多
文摘[Objectives]To prepare 20(S)-protopanaxadiol PLGA nanoparticles(20(S)-PPD-PLGA-NPs).[Methods]20(S)-PPD-PLGA-NPs were prepared by emulsion solvent evaporation method,and the optimal formulation was screened by Box-Behnken experiment with particle size and drug loading as the indicators through single factor experiment,and the drug release in vitro was carried out.[Results]The average diameter of the nanoparticles was(119.60±2.29)nm and the polydispersity index was(0.12±0.02),the size was uniform.The encapsulation efficiency and drug loading of protopanaxadiol were(87.99±1.29)%and(14.86±0.25)%,respectively.[Conclusions]The 20(S)-PPD-PLGA-NPs were successfully prepared by emulsion solvent evaporation method,and the 20(S)-PPD-PLGA-NPs had good stability,to lay a foundation for the study of 20(S)-PPD-PLGA-NPs in vitro and in vivo.
